Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief, including: 3D Medicines, Akers, Aldeyra, Algernon, Alphamab, Altimmune, Aptorum, Arcturus, Atyr, Beigene, Bellerophon, Benitec, Bioduro, Biogen, Biomérieux, Biosig, BMS, Cansino, Cerecor, Clover, Cobra, Covar, Cytodyn, Dynavax, Eisai, Eli Lilly, Gigagen, Gilead, Grifols, GSK, I-Mab, Imbio, Immuron, IMV, Innoplexus, Inovio, J&J, Kissei, Mabpharm, Mateon, Merck, Novartis, Noveome, Numab, Olix, Ono, Pfizer, Premas, Redhill, Resverlogix, Rising, Sanofi, Sanofi Pasteur, Simcere, Sorrento, Translate Bio, Vaxil, Vero, Vir, Vyripharm, Windtree, Wuxi.
Biopharmas in Asia-Pacific raising money in public or private financings, including: Hoth, Karolinska, Onethree, Svenska Vaccinfabriken Produktion.
New hires and promotions in the biopharma industry in Asia-Pacific, including: I-Mab Biopharma, Sosei Group.
The latest global regulatory news, changes and updates affecting biopharma, including: Association for Accessible Medicines, Department of Justice, EMA, FDA, Federal Trade Commission, International Coalition of Medicines Regulatory Authorities, SEC, White House, World Health Organization.
Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications, including: Altasciences, Cytodyn, Eagle, Healios, Immutep, Medimetriks, Opthea, Otsuka, Partner, Pluristem, Qurient, Regeneron, Revive, Roivant Sciences, Sanofi, Symbio.
Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific, including: Algernon, Astrazeneca, Beyondspring, Cstone, Daiichi Sankyo, Eisai, EMD Serono, Exelixis, Gilead Sciences, Humanigen, I-Mab, Junshi, Lupin, Mylan, Neurorx, Relief, Samsung Bioepis, Shenzhen Chipscreen Biosciences, Sumitomo Dainippon, Takeda.